How Polen was paid
$17.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Pension | Other | Total |
|---|---|---|---|---|---|---|---|
| Thomas E. PolenChairman, Chief Executive Officer and President | $1,395,463 | $9,991,854 | $3,311,861 | $1,852,010 | $236,700 | $341,251 | $17,129,140 |
| Christopher J. DelOreficeExecutive Vice President and Chief Financial Officer | $837,500 | $3,140,481 | $1,040,916 | $722,500 | $0 | $135,767 | $5,877,164 |
| Richard E. ByrdExecutive Vice President and President, Interventional Segment | $756,250 | $1,427,531 | $473,139 | $592,875 | $91,833 | $57,429 | $3,399,056 |
| Michael C. FeldExecutive Vice President, Chief Revenue Officer and President, Life Sciences Segment | $775,000 | $1,641,596 | $544,118 | $533,588 | $0 | $602,054 | $4,096,356 |
| Michael D. GarrisonExecutive Vice President and President, Medical Essentials and BioPharma Systems Segments | $768,750 | $1,641,596 | $544,118 | $533,588 | $102,800 | $58,188 | $3,649,040 |
What changed and why
- $17.1MCEO total compensation decreased slightly to $17,129,140 in fiscal year 2025 compared to $17,314,606 in fiscal year 2024.
- 72%Approximately 72% of the CEO total target compensation was weighted towards performance-based pay in fiscal year 2025.
- 89%At the 2025 annual meeting, approximately 89% of shares voted were cast in support of the advisory say-on-pay vote.
- $21.8BTotal revenues reached a record $21.8 billion for fiscal year 2025 alongside record adjusted diluted EPS of $14.40.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.